Breaking News
Get 50% Off 0
Final days! 🔥 Up to 50% OFF InvestingPro
CLAIM SALE
Close

Equillium Inc (EQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Equillium's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.950 +0.050    +2.63%
26/08 - Closed. Currency in USD
After Hours
1.950
-0.000
-0.000%
0:52:57 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,381,553
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.755 - 2.230
Equillium 1.950 +0.050 +2.63%

Equillium Inc Company Profile

 
Get an in-depth profile of Equillium Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

35

Equity Type

ORD

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Contact Information

Address 2223 Avenida De La Playa Suite 105
La Jolla, 92037
United States
Phone 858 240 1200
Fax -

Top Executives

Name Age Since Title
Mark Pruzanski 56 2018 Independent Director
Thomas O. Daniel 70 2019 Member of Scientific & Clinical Advisory Board
Vijay Kumar Kuchroo 69 - Member of Scientific & Clinical Advisory Board
Martha J. Demski 71 2018 Independent Director
Charles McDermott 52 2018 Independent Director
Bala S. Manian 79 2017 Independent Director
Fred Ramsdell 63 - Member of Scientific & Clinical Advisory Board
Barbara Troupin 56 2022 Independent Director
Peter Colabuono - 2024 Director
Bruce D. Steel 59 2006 Co-Founder, President, CEO & Director
Daniel Mark Bradbury 64 2017 Executive Chairman
Stephen Connelly 43 2017 Chief Scientific Officer & Director
Brian Gordon Feagan - 2025 Member of Scientific & Clinical Advisory Board
Bruce E. Sands - 2025 Member of Scientific & Clinical Advisory Board
Francisco J. Quintana - 2025 Member of Scientific & Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EQ Comments

Write your thoughts about Equillium Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email